Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond (original) (raw)

• Spivak, J. L. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin. Hematol. 41, 1–5 (2004).
  Article CAS PubMed Google Scholar
• Tefferi, A. & Vardiman, J. W. Classification and diagnosis of myeloproliferative neoplasms: the World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22, 14–22 (2008).
  Article CAS PubMed Google Scholar
• Spivak, J. L. Polycythemia vera: myths, mechanisms, and management. Blood 100, 4272–4290 (2002).
  Article CAS PubMed Google Scholar
• Beer, P. A. & Green, A. R. Pathogenesis and management of essential thrombocythemia. Hematology Am. Soc. Hematol. Educ. Program 2009, 621–628 (2009).
  Article Google Scholar
• Finazzi, G. & Barbui, T. How I treat patients with polycythemia vera. Blood 109, 5104–5111 (2007).
  Article CAS PubMed Google Scholar
• Passamonti, F. et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115, 1703–1708 (2010).
  Article CAS PubMed Google Scholar
• Schindler, C. & Darnell, J. E. Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64, 621–651 (1995).
  Article CAS PubMed Google Scholar
• Prchal, J. F. & Axelrad, A. A. Letter: Bone-marrow responses in polycythemia vera. N. Engl. J. Med. 290, 1382 (1974).
  CAS PubMed Google Scholar
• Lutton, J. D. & Levere, R. D. Endogenous erythroid colony formation by peripheral blood mononuclear cells from patients with myelofibrosis and polycythemia vera. Acta Haematol. 62, 94–99 (1979).
  Article CAS PubMed Google Scholar
• Adamson, J. W., Fialkow, P. J., Murphy S., Prchal, J. F. & Steinmann, L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N. Engl. J. Med. 295, 913–916 (1976).
  Article CAS PubMed Google Scholar
• Gilliland, D. G., Blanchard, K. L., Levy J., Perrin S. & Bunn, H. F. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc. Natl Acad. Sci. USA 88, 6848–6852 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• el Kassar, N., Hetet, G., Li, Y., Briere J. & Grandchamp, B. Clonal analysis of haemopoietic cells in essential thrombocythaemia. Br. J. Haematol. 90, 131–137 (1995).
  Article CAS PubMed Google Scholar
• Tsukamoto, N. et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br. J. Haematol. 86, 253–258 (1994).
  Article CAS PubMed Google Scholar
• Neubauer, H. et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397–409 (1998).
  Article CAS PubMed Google Scholar
• Parganas, E. et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 85–395 (1998).
  Article Google Scholar
• Levine, R. L., Pardanani, A., Tefferi, A. & Gilliland, D. G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Rev. Cancer 7, 673–683 (2007).
  Article CAS Google Scholar
• Moliterno, A. R., Hankins, W. D. & Spivak, J. L. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N. Engl. J. Med. 338, 572–580 (1998).
  Article CAS PubMed Google Scholar
• Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054–1061 (2005).
  Article CAS PubMed Google Scholar
• James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144–1148 (2005).
  Article CAS PubMed Google Scholar
• Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779–1790 (2005).
  Article CAS PubMed Google Scholar
• Levine, R. L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387–397 (2005).
  Article CAS PubMed Google Scholar
• Zhao, R. et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280, 22788–22792 (2005). References 18–22 provide the first description of the recurrent somatic mutation (JAK2V617F) in patients with PV, PMF and ET, thus molecularly linking all three disorders.
  Article CAS PubMed Google Scholar
• Lu, X. et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc. Natl Acad. Sci. USA 102, 18962–18967 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Dusa, A. et al. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J. Biol. Chem. 283, 12941–12948 (2008).
  Article CAS PubMed Google Scholar
• Scott, L. M. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459–468 (2007). This is the first description of mutations mapping to exon 12 of the JAK2 gene in patients with PV who do not carry the JAK2V617F mutation.
  Article CAS PubMed PubMed Central Google Scholar
• Pietra, D. et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111, 1686–1689 (2008).
  Article CAS PubMed Google Scholar
• Pardanani, A., Lasho, T. L., Finke, C., Hanson, C. A. & Tefferi, A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21, 1960–1963 (2007).
  Article CAS PubMed Google Scholar
• Wang, Y. L. et al. JAK2 mutations are present in all cases of polycythemia vera. Leukemia 22, 1289 (2008).
  Article CAS PubMed Google Scholar
• Jones, A. V. et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nature Genet. 41, 446–449 (2009).
  Article CAS PubMed Google Scholar
• Kilpivaara, O. et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2 _V617F_-positive myeloproliferative neoplasms. Nature Genet. 41, 455–459 (2009).
  Article CAS PubMed Google Scholar
• Olcaydu, D. et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nature Genet. 41, 450–454 (2009). References 29–31 describe the association between a specific haplotype and a high susceptibility risk to developing JAK2V617F-positive MPNs.
  Article CAS PubMed Google Scholar
• Saharinen, P., Takaluoma, K. & Silvennoinen, O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell Biol. 20, 3387–3395 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Lucet, I. S. et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176–183 (2006).
  Article CAS PubMed Google Scholar
• Silva, M. et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N. Engl. J. Med. 338, 564–571 (1998).
  Article CAS PubMed Google Scholar
• Jamieson, C. H. et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc. Natl Acad. Sci. USA 103, 6224–6229 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Ishii, T., Bruno, E., Hoffman R. & Xu, M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 108, 3128–3134 (2006).
  Article CAS PubMed Google Scholar
• Delhommeau, F. et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109, 71–77 (2007).
  Article CAS PubMed Google Scholar
• Lacout, C. et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108, 1652–1660 (2006).
  Article CAS PubMed Google Scholar
• Wernig, G. et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107, 4274–4281 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Zaleskas, V. M. et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1, e18 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Lippert, E. et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108, 1865–1867 (2006).
  Article CAS PubMed Google Scholar
• Tiedt, R. et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111, 3931–3940 (2008).
  Article CAS PubMed Google Scholar
• Nussenzveig, R. H. et al. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2009. Int. J. Hematol. 90, 58–63 (2001).
  Article CAS Google Scholar
• Shi, J. et al. An open-label assessment of the effects of CYP3A4 inhibitors on the PK/PD of INCB018424 in healthy subjects. J. Clin. Pharmacol. 49, (Abstr. 10) (2009).
• Shi, J. et al. An open-label assessment of the effects of rifampin, a potent CYP3A4 inducer on the PK/PD of INCB018424 in healthy subjects. J. Clin. Pharmacol. 49, (Abstr. 9) (2009).
• Verstovsek, S. et al. INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Blood 110, Abstr. 558 (2007).
• Verstovsek, S. et al. Safety and efficacy of a JAK1 & JAK2 inhibitor, INCB018424, in myelofibrosis. N. Engl. J. Med. 363, 1117–1127 (2010). This report describes the remarkable clinical activity of the oral JAK1 and JAK2 inhibitor INCB018424 (now known as ruxolitinib) in patients with post-ET or post-PV myelofibrosis.
  Article CAS PubMed PubMed Central Google Scholar
• Verstovsek, S. et al. A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera and essential thrombocythemia refractory to hydroxyurea. Blood 114, Abstr. 311 (2009).
• Barosi, G. et al. Response criteria for essential thrombocythemia and polycythemia vera: results of a European LeukemiaNet consensus conference. Blood 113, 4829–4833 (2009).
  Article CAS PubMed Google Scholar
• Wernig, G. et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13, 311–320 (2008).
  Article CAS PubMed Google Scholar
• Pardanani, A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22, 23–30 (2008).
  Article PubMed Google Scholar
• Pardanani, A. et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21, 1658–1668 (2007).
  Article CAS PubMed Google Scholar
• Pardanani, A. et al. A phase I study of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood 114, Abstr. 755 (2009).
• Hexner, E. O. et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111, 5663–5671 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Knapper, S. et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108, 3262–3270 (2006).
  Article CAS PubMed Google Scholar
• Smith, B. D. et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103, 3669–3676 (2004).
  Article CAS PubMed Google Scholar
• Marshall, J. L. et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest. New Drugs 23, 31–37 (2005).
  Article CAS PubMed Google Scholar
• Santos, F. P. et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115, 1131–1136 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hexner, E. et al. A multicenter, open label Phase I/II study of CEP701 (Lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the myeloproliferative disorders research consortium. Blood 114, Abstr. 754 (2009).
• Paquette, R. et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood 112, Abstr. 2810 (2008).
• Shah, N. et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood 112, Abstr. 98 (2008).
• Verstovsek, S. et al. Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Blood 114, Abstr. 3905 (2009).
• Hedvat, M. et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487–497 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Pardanani, A. et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 23, 1441–1445 (2009).
  Article CAS PubMed Google Scholar
• Tyner, J. W. et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115, 5232–5240 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Pardanani, A. et al. A Phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood 117, Abstr. 460 (2010).
• Changelian, P. S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875–878 (2003).
  Article CAS PubMed Google Scholar
• Williams, N. K. et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 387, 219–232 (2009).
  Article CAS PubMed Google Scholar
• Jiang, J. K. et al. Examining the chirality, conformation and selective kinase inhibition of 3-(3R, 4R)-4-methyl-3-(methyl(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)amino)piperi din-1-yl)-3-oxopropanenitrile (CP-690,550). J. Med. Chem. 51, 8012–8018 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Yabu, J. M. & Vincenti, F. Novel immunosuppression: small molecules and biologics. Semin. Nephrol. 27, 479–486 (2007).
  Article CAS PubMed Google Scholar
• Manshouri, T. et al. The JAK kinase inhibitor CP-690, 550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 99, 1265–1273 (2008).
  Article CAS PubMed Google Scholar
• Lacronique, V. et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309–1312 (1997).
  Article CAS PubMed Google Scholar
• Peeters, P. et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90, 2535–2540 (1997).
  CAS PubMed Google Scholar
• Schwaller, J. et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17, 5321–5333 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Ho, J. M., Beattie, B. K., Squire, J. A., Frank, D. A. & Barber, D. L. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93, 4354–4364 (1999).
  CAS PubMed Google Scholar
• Ward, A. C., Touw, I. & Yoshimura, A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95, 19–29 (2000).
  CAS PubMed Google Scholar
• Mullighan, C. G. et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 106, 9414–9418 (2009).
  Article PubMed PubMed Central Google Scholar
• Xiang, Z. et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 111, 4809–4812 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Walters, D. K. et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10, 65–75 (2006).
  Article CAS PubMed Google Scholar
• Lee, J. W. et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25, 1434–1436 (2006).
  Article CAS PubMed Google Scholar
• Jelinek, J. et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106, 3370–3373 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Williams, R. T., Roussel, M. F. & Sherr, C. J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 103, 6688–6693 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Samanta, A. K. et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 28, 1669–1681 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Vannucchi, A. M. et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110, 840–846 (2007).
  Article CAS PubMed Google Scholar
• Leonard, W. J. Cytokines and immunodeficiency diseases. Nature Rev. Immunol. 1, 200–208 (2001).
  Article CAS Google Scholar
• Kawamura, M. et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc. Natl Acad. Sci. USA 91, 6374–6378 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• O'Shea, J. J., Pesu, M., Borie, D. C. & Changelian, P. S. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nature Rev. Drug Discov. 3, 555–564 (2004).
  Article CAS Google Scholar
• Fridman, J. S. et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 184, 5298–5307 (2010).
  Article CAS PubMed Google Scholar
• Kremer, J. M. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60, 1895–1905 (2009).
  Article CAS PubMed Google Scholar
• Coombs, J. H. et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 69, 413–416 (2010).
  Article CAS PubMed Google Scholar
• Fleischmann, R. et al. Safety and efficacy after 24 week (wk) dosing of the oral JAK inhibitor CP-690550 (CP) as monotherapy in patients (pts) with active rheumatoid arthritis (RA). Arthritis Rheum. 60 (Suppl.10), 1924 (2009).
  Google Scholar
• Kremer, J. et al. Safety and efficacy after 24 week (WK) dosing of the oral JAK inhibitor CP-690550 (CP) in combination with methrotrexate (MTX) in patients (PTS) with active rheumatoid arthritis (RA). Arthritis Rheum. 60 (Suppl.10), 1925 (2009). References 89–92 describe a series of randomized, double-blind Phase II studies demonstrating remarkable activity of the potent JAK inhibitor tasocitinib (CP 690550) in patients with rheumatoid arthritis.
  Google Scholar
• Williams, W. et al. A randomized placebo-controlled study of INCB018424, a selective Janus kinase 1 & 2 (JAK1 & 2) inhibitor in rheumatoid arthritis (RA). Arthritis Rheum. 58, Abstr. 714 (2008).
• Punwani, N. et al. Efficacy and safety of topical INCB018424, a selective Janus kinase 1 and 2 (JAK1 and 2) inhibitor in psoriasis. J. Am. Acad. Dermatol. 60, Abstr. 176 (2009).
• Callis Duffin, K. et al. JAK 1 / Jak 2 inhibition: a novel mechanism in the treatment of chronic plaque psoriasis. in Society for Investigative Dermatology Meeting, Atlanta, Georgia, USA (2010).
  Google Scholar
• Pesu, M. et al. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol. Rev. 203, 127–142 (2005).
  Article CAS PubMed Google Scholar
• Quaedackers, M. E. et al. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 88, 1002–1009 (2009).
  Article CAS PubMed Google Scholar
• Busque, S. et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am. J. Transplant 9, 1936–1945 (2009).
  Article CAS PubMed Google Scholar
• van Gurp, E. A. et al. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 87, 79–86 (2009).
  Article CAS PubMed Google Scholar
• van Gurp, E. et al. Phase 1 dose-escalation study of CP-690550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am. J. Transplant. 8, 1711–1718 (2008).
  Article CAS PubMed Google Scholar
• Borie, D. C. et al. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation 80, 1756–1764 (2005).
  Article CAS PubMed Google Scholar
• Tefferi, A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24, 1128–1138 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Dawson, M. A. et al. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin. Nature 461, 819–822 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, Y. et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114, 5024–5033 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Marubayashi, S. et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J. Clin. Invest. 120, 3578–3593 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Di Nisio, M. et al. The haematocrit and platelet target in polycythemia vera. Br. J. Haematol. 136, 249–259 (2007).
  Article PubMed Google Scholar
• Najean, Y. & Rain, J. D. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 89, 2319–2327 (1997).
  CAS PubMed Google Scholar
• Cortelazzo, S. et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med. 332, 1132–1136 (1995).
  Article CAS PubMed Google Scholar
• Harrison, C. N. et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 353, 33–45 (2005).
  Article CAS PubMed Google Scholar
• Barbui, T. et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89, 215–232 (2004).
  CAS PubMed Google Scholar
• Arana-Yi, C. et al. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist 11, 929–943 (2006).
  Article CAS PubMed Google Scholar
• Mesa, R. A. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 113, 5394–5400 (2009).
  Article CAS PubMed Google Scholar
• Quintás-Cardama, A. et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J. Clin. Oncol. 27, 4760–4766 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Mesa, R. A. et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase-2 trial E4903. Blood 116, 4436–4438 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Cervantes, F. et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113, 2895–2901 (2009).
  Article CAS PubMed Google Scholar
• Bacigalupo, A. et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant. 45, 458–463 (2010).
  Article CAS PubMed Google Scholar
• Stewart, W. A. et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant. 45, 1587–1593 (2010).
  Article CAS PubMed Google Scholar
• Kroger, N. et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114, 5264–5270 (2009).
  Article CAS PubMed Google Scholar
• Kroger, N. & Mesa, R. A. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 22, 474–486 (2008).
  Article PubMed Google Scholar
• Rodig, S. J. et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93, 373–383 (1998).
  Article CAS PubMed Google Scholar
• Nosaka, T. et al. Defective lymphoid development in mice lacking Jak3. Science 270, 800–802 (1995).
  Article CAS PubMed Google Scholar
• Karaghiosoff, M. et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13, 549–560 (2000).
  Article CAS PubMed Google Scholar
• Shimoda, K. et al. Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function. Immunity 13, 561–571 (2000).
  Article CAS PubMed Google Scholar
• Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461–1463 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Burton, P. R. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genet. 39, 1329–1337 (2007).
  Article CAS PubMed Google Scholar
• Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Pardanani, A. D. et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108, 3472–3476 (2006).
  Article CAS PubMed Google Scholar
• Vannucchi, A. M. et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112, 844–847 (2008).
  Article CAS PubMed Google Scholar
• Beer, P. A. et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112, 141–149 (2008).
  Article CAS PubMed Google Scholar
• Chaligne, R. et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 110, 3735–3743 (2007).
  Article CAS PubMed Google Scholar
• Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLOS Med. 3, e270 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Bersenev, A. et al. Lnk constrains myeloproliferative diseases in mice. J. Clin. Invest. 120, 2058–2069 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Oh, S. T. et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116, 988–992 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lasho, T. L., Pardanani, A. & Tefferi, A. LNK mutations in JAK2 mutation-negative erythrocytosis. N. Engl. J. Med. 363, 1189–1190 (2010).
  Article CAS PubMed Google Scholar
• Dupont, S. et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110, 1013–1021 (2007).
  Article CAS PubMed Google Scholar
• Theocharides, A. et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110, 375–379 (2007).
  Article CAS PubMed Google Scholar
• Kralovics, R. et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108, 1377–1380 (2006).
  Article CAS PubMed Google Scholar
• Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009). This study is the first to describe mutations in TET2 in patients with myeloid cancers and proposes TET2 mutations as antecedent molecular events to the acquisition of the JAK2V617F mutation.
  Article PubMed Google Scholar
• Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ito, S. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129–1133 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tefferi, A. et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23, 905–911 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Carbuccia, N. et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23, 2183–2186 (2009).
  Article CAS PubMed Google Scholar
• Abdel-Wahab, O. et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 70, 447–452 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Grand, F. H. et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113, 6182–6192 (2009).
  Article CAS PubMed Google Scholar
• Green, A. & Beer, P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N. Engl. J. Med. 362, 369–370 (2010).
  Article CAS PubMed Google Scholar
• Pardanani, A. et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 24, 1146–1151 (2010).
  Article CAS PubMed Google Scholar
• Tefferi, A. et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24, 1302–1309 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Jager, R. et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 24, 1290–1298 (2010).
  Article CAS PubMed Google Scholar
• Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genet. 42, 722–726 (2010).
  Article CAS PubMed Google Scholar
• Bumm, T. G. et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 66, 11156–11165 (2006).
  Article CAS PubMed Google Scholar
• Xing, S. et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111, 5109–5117 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Mullally, A. et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17, 584–596 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Akada, H. et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115, 3589–3597 (2010). References 152 and 153 describe mouse models of JAK2V617F-positive MPNs in which the mutant JAK2V617F is expressed from its endogenous promoter, and the authors suggest that JAK2 inhibitor therapy does not eradicate the disease-initiating cells.
  Article CAS PubMed PubMed Central Google Scholar
• Levine, R. L. & Gilliland, D. G. Myeloproliferative disorders. Blood 112, 2190–2198 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Morgan, K. J. & Gilliland, D. G. A role for JAK2 mutations in myeloproliferative diseases. Annu. Rev. Med. 59, 213–222 (2008).
  Article CAS PubMed Google Scholar
• Roder, S., Steimle, C., Meinhardt, G. & Pahl, H. L. STAT3 is constitutively active in some patients with polycythemia rubra vera. Exp. Hematol. 29, 694–702 (2001).
  Article CAS PubMed Google Scholar
• Komura, E. et al. Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Exp. Hematol. 31, 622–630 (2003).
  Article CAS PubMed Google Scholar
• Jamieson, C. H., Barroga, C. F. & Vainchenker, W. P. Miscreant myeloproliferative disorder stem cells. Leukemia 22, 2011–2019 (2008).
  Article PubMed Google Scholar
• Kota, J., Caceres, N. & Constantinescu, S. N. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 22, 1828–1840 (2008).
  Article PubMed Google Scholar
• Quintás-Cardama, A. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109–3117 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ugo, V. et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp. Hematol. 32, 179–187 (2004).
  Article CAS PubMed Google Scholar
• Shi, S. et al. JAK signaling globally counteracts heterochromatic gene silencing. Nature Genet. 38, 1071–1076 (2006).
  Article CAS PubMed Google Scholar
• Liu, P. C. et al. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity. Clin. Cancer Res. 15, 6891–6900 (2009).
  Article CAS PubMed Google Scholar
• Baffert, F. et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol. Cancer Ther. 9, 1945–1955 (2010).
  Article CAS PubMed Google Scholar
• Passamonti, F. et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 11 Jan 2011 [epub ahead of print]
• Scott, L. M. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459–468 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Moliterno, A. R. et al. An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. Blood 114, Abstr. 753 (2009).
• Seymour, F. et al. First report of the phase-I study of the novel oral JAK2 inhibitor sb1518 in patients with myelofibrosis. Haematologica 95 (Suppl. 2), Abstr. 1144 (2010).